Hollis-Eden price target cut by Jefferies

Hollis-Eden Pharmaceuticals Inc. was maintained by Jefferies & Co. analyst Adam Walsh at a buy rating but the price target on the stock was reduced to $11 per share from $22, due to uncertainties surrounding the timeline for its radiation protection treatment Neumune. Hollis-Eden shares Wednesday gained $0.06, or 0.69%, to close at $8.73 on volume of 156,878 shares versus the three-month running average of 198,428 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.